OPT Opthea Limited ADRs
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$4.20 +0.00 (0.01%)
As of 03/22/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Australia
Country of incorporation:
IPO date: 04/12/2012
Outstanding shares: 58,394,929
Average volume: 3,982
Market cap: $245,270,381
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%